急性冠脉综合征计划行经皮冠状动脉介入治疗前负荷剂量阿托伐他汀对主要不良心血管事件的影响:SECURE-PCI随机临床试验
SECURE-PCI是一项在巴西53个中心开展的多中心、双盲、安慰剂对照随机临床试验,纳入4191例急性冠脉综合征并计划行冠状动脉造影、若解剖可行则行经皮冠状动脉介入治疗的患者。患者随机接受阿托伐他汀80 mg两次负荷剂量(n=2087)或匹配安慰剂(n=2104),分别在计划PCI前和PCI后24小时给药;所有患者从第二次研究药物后24小时开始接受阿托伐他汀40 mg治疗30天。30天时,阿托伐他汀组130例(6.2%)发生MACE,安慰剂组149例(7.1%),绝对差异0.85%(95%CI -0.70%至2.41%),HR 0.88(95%CI 0.69-1.11),P=0.27。作者结论认为,围术期负荷剂量阿托伐他汀未减少30天MACE,不支持在未选择的急性冠脉综合征并计划侵入性管理的患者中常规使用负荷剂量。
要点
- 在计划行侵入性管理的急性冠脉综合征患者中,围术期阿托伐他汀80 mg两次负荷剂量未降低30天MACE(6.2% vs 7.1%,HR 0.88,95%CI 0.69-1.11,P=0.27)。
- MACE定义为30天内全因死亡、心肌梗死、卒中及非计划冠状动脉血运重建的复合终点。
- 4191例患者中2710例(64.7%)接受PCI,333例(8%)接受冠状动脉旁路移植术,1144例(27.3%)仅药物治疗。
- 安慰剂组报告3例横纹肌溶解(0.1%),阿托伐他汀组0例;未报告肝衰竭病例。
- 作者结论:这些发现不支持在未选择的急性冠脉综合征并计划侵入性管理的患者中常规使用阿托伐他汀负荷剂量。
适用人群与场景
- 急性冠脉综合征并计划行侵入性管理、经冠状动脉造影评估若解剖可行则行经皮冠状动脉介入治疗的患者。
- 研究纳入4191例患者,平均年龄61.8岁(SD 11.5),女性1085例(25.9%)。
- 研究在巴西53个中心开展,入组时间为2012年4月18日至2017年10月6日。
处置流程与药物剂量
- 阿托伐他汀组接受2次负荷剂量阿托伐他汀80 mg,分别在计划PCI前和PCI后24小时给药(n=2087)。
- 安慰剂组接受匹配安慰剂,给药时间点同阿托伐他汀组(n=2104)。
- 所有患者从第二次研究药物给药后24小时开始接受阿托伐他汀40 mg治疗30天。
研究设计与关键结果
- 研究类型:多中心、双盲、安慰剂对照随机临床试验,在巴西53个中心开展,纳入4191例急性冠脉综合征并计划行侵入性管理的患者。
- 干预与对照:阿托伐他汀80 mg两次负荷剂量(n=2087)vs 匹配安慰剂(n=2104),分别在计划PCI前和PCI后24小时给药。
- 主要终点:30天MACE(全因死亡、心肌梗死、卒中及非计划冠状动脉血运重建的复合终点),阿托伐他汀组130例(6.2%)vs 安慰剂组149例(7.1%),绝对差异0.85%(95%CI -0.70%至2.41%),HR 0.88(95%CI 0.69-1.11),P=0.27。
- 4163例(99.3%)完成30天随访;2710例(64.7%)接受PCI,333例(8%)接受冠状动脉旁路移植术,1144例(27.3%)仅药物治疗。
- 安全性:未报告肝衰竭病例;安慰剂组报告3例横纹肌溶解(0.1%),阿托伐他汀组0例。
证据类型、等级与局限
- 证据类型:多中心、双盲、安慰剂对照随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在未选择的急性冠脉综合征并计划侵入性管理的患者中,围术期负荷剂量阿托伐他汀未减少30天MACE,这些发现不支持常规使用负荷剂量。
- 所有患者从第二次研究药物给药后24小时开始接受阿托伐他汀40 mg治疗30天。
指南或共识出处
- SECURE-PCI随机临床试验,临床试验注册号NCT01448642。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The effects of loading doses of statins on clinical outcomes in patients with acute coronary syndrome (ACS) and planned invasive management remain uncertain.
OBJECTIVE: To determine if periprocedural loading doses of atorvastatin decrease 30-day major adverse cardiovascular events (MACE) in patients with ACS and planned invasive management.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled, randomized clinical trial conducted at 53 sites in Brazil among 4191 patients with ACS evaluated with coronary angiography to proceed with a percutaneous coronary intervention (PCI) if anatomically feasible. Enrollment occurred between April 18, 2012, and October 6, 2017. Final follow-up for 30-day outcomes was on November 6, 2017.
INTERVENTIONS: Patients were randomized to receive 2 loading doses of 80 mg of atorvastatin (n = 2087) or matching placebo (n = 2104) before and 24 hours after a planned PCI. All patients received 40 mg of atorvastatin for 30 days starting 24 hours after the second dose of study medication.
MAIN OUTCOMES AND MEASURES: The primary outcome was MACE, defined as a composite of all-cause mortality, myocardial infarction, stroke, and unplanned coronary revascularization through 30 days.
RESULTS: Among the 4191 patients (mean age, 61.8 [SD, 11.5] years; 1085 women [25.9%]) enrolled, 4163 (99.3%) completed 30-day follow-up. A total of 2710 (64.7%) underwent PCI, 333 (8%) underwent coronary artery bypass graft surgery, and 1144 (27.3%) had exclusively medical management. At 30 days, 130 patients in the atorvastatin group (6.2%) and 149 in the placebo group (7.1%) had a MACE (absolute difference, 0.85% [95% CI, -0.70% to 2.41%]; hazard ratio, 0.88; 95% CI, 0.69-1.11; P = .27). No cases of hepatic failure were reported; 3 cases of rhabdomyolysis were reported in the placebo group (0.1%) and 0 in the atorvastatin group.
CONCLUSIONS AND RELEVANCE: Among patients with ACS and planned invasive management with PCI, periprocedural loading doses of atorvastatin did not reduce the rate of MACE at 30 days. These findings do not support the routine use of loading doses of atorvastatin among unselected patients with ACS and intended invasive management.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01448642.
参考来源
- Berwanger O, Santucci EV, de Barros E Silva PGM, et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA. 2018. PMID: 29525821. doi:10.1001/jama.2018.2444
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。